Cellectis patent dispute sees key amendment approval by Indian court
French biopharma company Cellectis has been granted permission by an Indian court to amend its patent specification for its T-cell immunotherapy technology, in a ruling that marks a significant development in patent...To view the full article, register now.
Already a subscriber? Click here to view full article